DexCom, Inc. (DXCM) Stock Price & How to Invest

DexCom is a medical-device company that pioneered continuous glucose monitoring. Its wearable sensors and transmitters measure glucose levels continuously and send readings to a phone or receiver, replacing or supplementing traditional fingerstick tests for people with diabetes. Its flagship G7 platform serves people with type 1 and type 2 diabetes, while Stelo, an over-the-counter CGM cleared for people who do not use insulin, extends the technology toward a broader wellness and metabolic-health audience. DexCom earns most of its revenue from recurring sensor sales, since users replace sensors regularly, which gives the business a razor-and-blade-like recurring quality once a patient is on the platform.

The investment picture in mid-2026 is one of durable, high growth. In Q1 2026 DexCom reported revenue of about $1.19 billion, up roughly 15% year over year, with net income of about $199.5 million, or $0.51 per share, a sharp bottom-line gain. The company reiterated 2026 revenue guidance of $5.16 to $5.25 billion and pointed to several growth levers: the expanded launch of its G7 15 Day sensor across US channels, new Smart Meal Logging features on the Stelo consumer platform, FDA clearance of Stelo for children as young as two who do not use insulin, and broadening insurance coverage, including a Prime Therapeutics agreement expected to help push its covered type 2 non-insulin population above seven million by year end. DexCom also agreed to acquire NutriSense to bolster its consumer metabolic-health offering. The core tension is that DexCom carries a premium valuation tied to sustained growth, in a market it largely shares with Abbott, so execution and competition matter a great deal.

The main risk is that DexCom carries a premium valuation built on continued high growth, so any slowdown, guidance cut, or margin disappointment can pressure the stock sharply. Competition is significant: Abbott's FreeStyle Libre is a large, well-funded rival in CGM, and price competition or feature gaps could cost DexCom share, while Medtronic and newer entrants add pressure. Reimbursement is pivotal and outside DexCom's full control, so unfavorable coverage or pricing decisions by insurers and pharmacy-benefit managers could slow adoption. As a device maker, DexCom faces regulatory, manufacturing, and product-quality risks; a recall or supply issue would hurt. The push into the consumer and over-the-counter wellness market is newer and less proven than the medical diabetes business, so returns there are less certain. Acquisitions like NutriSense add integration risk. International expansion and currency swings add further variables.

25 analysts publish price targets on DXCM, averaging $92.80 against a $83.45 price as of August 2026, or +11.2%. The published targets run from $79.00 to $115.00, a moderate spread, and the ratings split 25 buy, 3 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full DXCM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on DexCom, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Expansion beyond insulin users. DexCom's largest opportunity is extending CGM from insulin-dependent patients to the far larger type 2 non-insulin and consumer wellness populations. The most optimistic published target, $115.00, assumes this works close to its best case.

The case against. The main risk is that DexCom carries a premium valuation built on continued high growth, so any slowdown, guidance cut, or margin disappointment can pressure the stock sharply. The most pessimistic target, $79.00, is roughly what DXCM is worth if this bites instead.

Read the full bull and bear case on DXCM, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see DexCom, Inc.'s investor relations page or your broker.

• Revenue (Q1 2026): ~$1.19 billion, up about 15% year over year
• Net income (Q1 2026): ~$199.5 million, or about $0.51 per share
• 2026 revenue guidance: $5.16 to $5.25 billion (reiterated)
• Coverage expansion: targeting more than 7 million covered type 2 non-insulin lives by year end
• Key products: G7 15 Day sensor; Stelo over-the-counter CGM
• Recent M&A: agreed to acquire NutriSense to expand consumer metabolic health

Figures are approximate and tied to the asOf date; verify live numbers before acting. DexCom typically trades at a premium valuation that reflects expectations for sustained double-digit growth, so its earnings multiple tends to be higher than the broader market; that premium leaves less room for error if growth slows or competition intensifies. Investors should weigh the CGM growth runway and coverage momentum against that elevated valuation and Abbott's competitive presence.

Other names that sit close to DXCM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get DXCM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so DXCM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where DXCM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

DexCom is a leading, fast-growing maker of continuous glucose monitors expanding from insulin users toward the far larger type 2 and consumer markets, backed by new products and widening insurance coverage. It rewards continued double-digit growth and execution, but as a premium-valued device leader it faces real competition and high expectations.

Whether DXCM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DXCM a buy or a sell?, and where the stock could go from here in the DXCM stock forecast.

For income investors, whether DXCM pays a dividend and how the payout looks is covered in does DXCM pay a dividend? And to weigh DXCM against a peer, read the full side-by-side comparisons: DXCM vs ABT and DXCM vs MDT.